GleamWall
中文EN

CRON Cronos Group Inc.

Medicinal Chemicals & Botanical Products · Nasdaq · SEC CIK 1656472 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY55.8%
TTM net income YoY60.2%
TTM EPS YoY60.0%
Revenue 3-yr CAGR34.2%
Net income 3-yr CAGR—

Margins

Gross margin46.6%
Operating margin3.4%
Net margin28.0%
FCF margin31.7%
EBITDA margin7.4%

Returns

ROE5.4%
ROA4.9%
ROIC (approx.)1.5%
Asset turnover0.17x

Leverage & solvency

Liabilities / assets6.1%
Debt / equity0.00x
Current ratio12.71x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.40x
Accruals ratio-2.0%
Payout ratio—
Capex / revenue7.6%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$63.45M$53.01M$45.21M$44.53M$36.34M$33.45M$32.26M$30.30M
Gross profit$32.28M$28.45M$19.15M$16.19M$18.33M$14.50M$13.73M$10.81M
R&D expense$1.34M$1.22M$1.41M$1.38M$1.34M$929,000$793,000$1.03M
SG&A expense$12.00M$10.80M$11.74M$12.90M$9.25M$10.54M$9.31M$12.08M
Operating income$9.03M$7.40M-$1.83M-$7.50M-$503,000-$5.32M-$4.07M-$11.37M
Pretax income$18.72M$35.71M$18.14M-$12.39M$27.00M-$39.01M$7.27M$45.95M
Income tax$898,000$51,000$2.43M-$11.89M-$1.32M-$525,000-$455,000$2.00M
Net income$13.80M$32.09M$13.75M-$1.82M$25.96M-$39.71M$6.12M$43.73M
EBITDA$9.38M$7.78M$1.89M-$3.84M-$149,000-$4.46M-$1.23M-$8.84M
EPS (basic)0.040.090.04—0.07-0.100.02—
EPS (diluted)0.040.090.04—0.07-0.100.02—
Weighted avg. shares (diluted)370.72M375.06M381.80M—384.99M385.31M386.96M—
Balance sheet
Cash & equivalents$411.19M$467.02M$821.86M$791.79M$784.17M$794.42M$797.82M$858.80M
Short-term investments$329.98M$330.00M$0$40.00M$40.00M$40.00M$40.00M$0
Receivables$44.23M$36.72M$32.96M$34.10M$27.09M$26.62M$18.71M$15.46M
Inventory$54.52M$52.70M$48.68M$46.75M$48.17M$42.14M$34.60M$33.15M
Current assets$859.31M$912.03M$927.88M$944.09M$922.15M$927.15M$918.58M$936.11M
PP&E, net$144.05M$141.54M$142.10M$145.87M$145.54M$150.24M$139.19M$133.19M
Goodwill$63.98M$64.15M$65.44M$66.48M$65.41M$66.92M$63.27M$63.45M
Intangibles$7.65M$8.05M$8.55M$8.89M$9.83M$10.56M$10.62M$11.26M
Total assets$1.20B$1.18B$1.17B$1.20B$1.18B$1.18B$1.15B$1.17B
Current liabilities$67.59M$56.36M$42.42M$48.19M$41.07M$37.61M$33.05M$49.70M
Total liabilities$73.40M$62.41M$48.30M$54.18M$46.36M$45.02M$39.06M$55.33M
Shareholders' equity$1.07B$1.07B$1.07B$1.09B$1.08B$1.08B$1.07B$1.06B
Shares outstanding367.53M370.73M376.26M381.59M382.89M383.81M385.41M382.53M
Cash flow statement
Operating cash flow$34.34M$24.01M$10.90M$11.84M$13.31M$2.82M-$2.10M$7.72M
Capital expenditure$9.95M$1.74M$1.88M$2.14M$4.48M$3.84M$15.26M$3.54M
Free cash flow$24.39M$22.27M$9.02M$9.70M$8.83M-$1.02M-$17.35M$4.18M
Investing cash flow-$75.65M-$358.30M$38.03M$2.78M-$23.00M-$983,000-$55.36M-$5.03M
Financing cash flow-$9.42M-$20.88M-$18.27M-$7.42M-$1.87M-$7.69M-$2.93M-$313,000
Depreciation & amortization$359,000$379,000$3.73M$3.66M$354,000$867,000$2.84M$2.52M
Stock-based compensation$2.31M$1.56M$1.31M$1.25M$2.33M$1.38M$2.09M$2.19M
Share buybacks$9.41M$16.13M$16.73M$4.27M$1.86M$3.61M$0$0

Free plan shows the latest 8 periods; Pro shows all 35 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.